| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 04/22/2004 | WO2002100148A3 Treatment or prophylaxis of insulin-producing cell graft rejection |
| 04/22/2004 | WO2002074767A8 Metalloproteinase inhibitors |
| 04/22/2004 | WO2002074752A8 Metalloproteinase inhibitors |
| 04/22/2004 | WO2002074748A8 Metalloproteinase inhibitors |
| 04/22/2004 | US20040077900 Process for the preparation of a highly pure pharmaceutical intermediate, 4-(cyclopropylcarbonyl)-alpha, alpha-dimethylphenylacetic acid |
| 04/22/2004 | US20040077877 Jun n-terminal kinase inhibitors |
| 04/22/2004 | US20040077875 (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2 -thiazolyl)carbamic Acid, 1,1-dimethylethyl ester for example; treating immunological and oncological disorders such as inflammatory bowel disease or cancer |
| 04/22/2004 | US20040077858 Making 4-(1H-indol-5-yloxy)-pyrrolo(2,1-f)(1,2,4)triazine compounds that are tyrosine kinase inhibitors; reducing vascular permeability; anticancer agents |
| 04/22/2004 | US20040077854 4-chloro-N-((5-((4-(hexylamino)piperidin-1-yl)sulfonyl)thien-2 -yl)methyl)benzamide for example; JUN kinase inhibitors to treat nervous system disorders, cancer, cardiovascular and autoimmune disorders |
| 04/22/2004 | US20040077851 Receptor selective cannabimimetic aminoalkylindoles |
| 04/22/2004 | US20040077842 First antigen recognition portion that binds a C3b-like receptor and a second that binds an antigenic molecule present in the circulatory system |
| 04/22/2004 | US20040077837 Microtubule-associated proteins and tubulins |
| 04/22/2004 | US20040077727 Hydroxamic acid derivative as inhibitor of the formation of soluble human CD23 |
| 04/22/2004 | US20040077695 Anticarcinogenic, antiallergen, and antiinflammatory agents; autoimmuned diseases |
| 04/22/2004 | US20040077693 Integrin receptor inhibitors |
| 04/22/2004 | US20040077687 Thiazolmines and their use as tgf-beta inhibitors |
| 04/22/2004 | US20040077681 Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors |
| 04/22/2004 | US20040077680 Ureaacylated indazole, benzisoxazole, or benzisothiazole derivative with monocyte chemoattractant protein inhibitors; antiinflammatory agents; autoimmune diseases; arthritis, asthma, atherosclerosis, diabetes |
| 04/22/2004 | US20040077678 Urea substituted imidazoquinoline ethers |
| 04/22/2004 | US20040077668 Compounds, compositins, and methods |
| 04/22/2004 | US20040077667 Quinazolinone derivatives |
| 04/22/2004 | US20040077664 Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates |
| 04/22/2004 | US20040077663 Thienopyrimidine-based inhibitors of the src family |
| 04/22/2004 | US20040077658 Respiratory system, nervous system, brain, gastrointestinal and psychological disorders; chronic obstructive pulmonary disease; antiasthmatics, analgesics |
| 04/22/2004 | US20040077649 Novel cannabimimetic ligands |
| 04/22/2004 | US20040077645 Xanthine derivatives,production and use thereof as medicament |
| 04/22/2004 | US20040077643 3,4 Dihydroisoquinoline derivative compounds and drugs containing these compounds as the active ingredient |
| 04/22/2004 | US20040077639 Administering amidine derivative as antiasthmatic agents; chronic obstructive pulmonary disease treatment |
| 04/22/2004 | US20040077632 Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein junkinases |
| 04/22/2004 | US20040077614 High, sustained blood concentration levels even during pregnacy without hepatic side effects; 3,17-dipropionate or dihexanoate; multiple sclerosis |
| 04/22/2004 | US20040077612 Acting as prodrugs; higher concentration delivery of active material to target cell in hybrid form; decreasing side effects |
| 04/22/2004 | US20040077610 Medicament containing a polyamine as an active substance |
| 04/22/2004 | US20040077577 Gene therapy; vaccines; inducing antibodies and/or cytotoxic or helper T lymphocytes |
| 04/22/2004 | US20040077552 Inflammation-inhibiting compounds |
| 04/22/2004 | US20040077535 Novel physiologically active peptide and use thereof |
| 04/22/2004 | US20040077086 Animal protein free media for cultivation of cells |
| 04/22/2004 | US20040076991 Modified interleukin-1 receptor antagonist(il-1ra) with reduced immunogenicity |
| 04/22/2004 | US20040076985 Reagents which regulate human chemokine-like receptor and reagents which bind to human chemokine-like receptor gene products, useful in preventing, ameliorating, or correcting dysfunctions or diseases including HIV infection, |
| 04/22/2004 | US20040076639 Antiallergens is encoded from Mycobacterium, genetic vaccines, for immunotherapy treating atopic dermatitis, asthma, rhinitis, or conjunctivitis, as immunosuppressants inhibiting the production of interleukin-4 |
| 04/22/2004 | US20040076633 Genetic vaccines comprising a 1H-imidazo(4,5-c)- 4-amine derivative as an adjuvant, for increasing immune responses in a mammal to the encoded antigen |
| 04/22/2004 | US20040076627 Humanised antibodies |
| 04/22/2004 | US20040076626 Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L |
| 04/22/2004 | US20040076625 A fusion proteins comprising self or non-self antigens, is used for treatment and prevention of immunoglobulin E related diseases, gene expression |
| 04/22/2004 | US20040076614 For natural cellular immune defense in humans/animals; for foods/feeds |
| 04/22/2004 | US20040076608 Cytokine uses; compositions; methods |
| 04/22/2004 | DE10153346A1 Substituierte Indole Substituted indoles |
| 04/22/2004 | CA2823937A1 Hiv vaccine formulations |
| 04/22/2004 | CA2820949A1 Novel immunogenic proteins of leptospira |
| 04/22/2004 | CA2501807A1 Treatment of allergic conditions by use of il 21 |
| 04/22/2004 | CA2500385A1 Styrylacrylonitrile compounds for inhibition of vascular endothelial growth factor |
| 04/21/2004 | EP1411064A2 Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours |
| 04/21/2004 | EP1410822A1 Oxa(thia)zolidine compounds, process for preparation thereof and anti-inflammatory agents |
| 04/21/2004 | EP1410820A2 Nasal delivery devices |
| 04/21/2004 | EP1410805A1 Vaccine against HPV |
| 04/21/2004 | EP1410802A1 Cell death inducers for mast cells |
| 04/21/2004 | EP1410798A2 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
| 04/21/2004 | EP1410795A1 Remedies for allergic eye diseases |
| 04/21/2004 | EP1410305A2 Method and apparatus for computer modeling of an adaptive immune response |
| 04/21/2004 | EP1410018A1 Method for detecting modultators of notch signalling |
| 04/21/2004 | EP1409737A2 Methods for detecting and treating the early onset of aging-related conditions |
| 04/21/2004 | EP1409715A2 Methods and materials relating to neurotrimin-like polypeptides and polynucleotides |
| 04/21/2004 | EP1409694A1 Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof |
| 04/21/2004 | EP1409684A1 Novel surface exposed immunoglobulin d-binding protein from moraxella catarrhalis |
| 04/21/2004 | EP1409683A2 i HELICOBACTER /i PROTEINS, NUCLEIC ACIDS AND USES THEREOF |
| 04/21/2004 | EP1409677A2 Receptors and membrane-associated proteins |
| 04/21/2004 | EP1409673A2 Human leucine-rich repeat containing protein, expressed predominantely in small intestine, hlrrsi1 |
| 04/21/2004 | EP1409655A2 Immunoglobulin superfamily proteins |
| 04/21/2004 | EP1409650A1 Ex-vivo isolated cd25+cd4+ t cells with immunosuppressive activity and uses thereof |
| 04/21/2004 | EP1409645A1 Probiotic lactobacillus salivarius strains |
| 04/21/2004 | EP1409644A1 Probiotic bifidobacterium strains |
| 04/21/2004 | EP1409643A1 Probiotic lactobacillus casei strains |
| 04/21/2004 | EP1409550A1 Extracellular messengers |
| 04/21/2004 | EP1409542A2 Blood group antigen fusion polypeptides and methods of use thereof |
| 04/21/2004 | EP1409539A1 Method for obtaining a tgf-beta enriched protein fraction in activated form, protein fraction and therapeutic applications |
| 04/21/2004 | EP1409535A2 Human secreted proteins |
| 04/21/2004 | EP1409527A1 Novel human cytomegalovirus (hcmv) cytotoxic t cell epitopes, polyepitopes, compositions comprising same and diagnostic and prophylactic and therapeutic uses therefor |
| 04/21/2004 | EP1409523A2 Pancam nucleic acids and polypeptides |
| 04/21/2004 | EP1409491A2 Thienopyrimidine-based inhibitors of the src family |
| 04/21/2004 | EP1409489A1 6-phenyldihydropyrrolopyrimidinedione derivatives |
| 04/21/2004 | EP1409485A1 Novel immunomodulating compounds |
| 04/21/2004 | EP1409483A1 Arylsulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors |
| 04/21/2004 | EP1409466A2 Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis |
| 04/21/2004 | EP1409463A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 04/21/2004 | EP1409455A1 Prostaglandin analogues-as ep4 receptor agonists |
| 04/21/2004 | EP1409077A2 Thermotherapy via targeted delivery of nanoscale magnetic particles |
| 04/21/2004 | EP1409016A2 Antibodies to opgl |
| 04/21/2004 | EP1409015A1 Methods for treating or preventing skin disorders using cd2-binding agents |
| 04/21/2004 | EP1409011A1 Prime-boost vaccination strategy |
| 04/21/2004 | EP1409009A1 Therapeutical vaccination |
| 04/21/2004 | EP1409007A2 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof |
| 04/21/2004 | EP1409006A2 Methods of treating diabetes mellitus |
| 04/21/2004 | EP1409005A1 Modulators of notch signalling for use in immunotherapy |
| 04/21/2004 | EP1409000A4 Use of agaricus blazei murill to prevent or treat skin and other disorders |
| 04/21/2004 | EP1409000A1 Use of agaricus blazei murill to prevent or treat skin and other disorders |
| 04/21/2004 | EP1408995A1 Modulating serum amyloid a interaction with tanis and agents useful for same |
| 04/21/2004 | EP1408989A2 Method and material for treating immune diseases |
| 04/21/2004 | EP1408984A2 Organo-phosphorous compounds for activating gamma/delta t cells |
| 04/21/2004 | EP1408967A2 Novel pharmaceutical compositions based on anticholinergic agents, corticosteroids and betamimetic agents for the treatment of inflammatory and/or obstructive respiratory tract diseases |
| 04/21/2004 | EP1408959A1 Use of galiella lactone |
| 04/21/2004 | EP1408941A2 Pharmaceutical composition and method of using the same |